Cormedix Inc

CRMD's Fundamental analysis

Select the Comparisons :

None ▼

Select the Ratio:

None▼

None ▼

None▼

CRMD Growth rates comparisons

Looking into Cormedix Inc growth rates, revenue grew in the second quarter of 2025 from the same quarter a year ago. Ranking at No. 172

Major Pharmaceutical Preparations industry recorded growth of revenues by 8.14 %

Cormedix Inc realized net income compared to net loss a year ago in second quarter of 2025

• More on CRMD's Growth

CRMD's Valuation comparisons

Cormedix Inc
current PE on trailing twelve month basis is above Major Pharmaceutical Preparations industry average.

Cormedix Inc PEG ratio is at -1.09 Company is currently trading with Price to Cash flow multiple of 7.65 in trailing twelve-month period.

Company

121.33

PE TTM

Industry

PE TTM

Company's Price to Sales ratio is at 9.97.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.87.

• More on CRMD's Valuation

Total Debt (Millions $)	-
Dividend TTM ($)	0 $
Dividend Yield TTM (%)	-
Revenue/Employee (TTM) $	3,328,358
Net Income/Employee (TTM) $	465,693
Receivable Turnover (TTM)	2.97
Tangible Book Value (Per Share $)	3.04

CRMD's Valuation comparisons

Company

121.33

PE TTM

Industry

PE TTM

Company's Price to Sales ratio is at 9.97.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.87.

Cormedix Inc Price to Book Ratio is at 3.76 lower than Industry Avg. of 39.17. and higher than S&P 500 Avg. of 0.02

• More on CRMD's Valuation

• Market Capitalization (Millions $)	830
• Shares Outstanding (Millions)	72
• Employees	25
• Revenues (TTM) (Millions $)	83
• Net Income (TTM) (Millions $)	12
• Cash Flow (TTM) (Millions $)	109
• Capital Exp. (TTM) (Millions $)	-
• Total Debt (Millions $)	-
• Dividend TTM ($)	0 $
• Dividend Yield TTM (%)	-
• Revenue/Employee (TTM) $	3,328,358
• Net Income/Employee(TTM) $	465,693
• Receivable Turnover Ratio (TTM)	2.97
• Tangible Book Value (Per Share $)	3.04

• Market Capitalization (Millions $)	830
• Shares Outstanding (Millions)	72
• Employees	25
• Revenues (TTM) (Millions $)	83
• Net Income (TTM) (Millions $)	12
• Cash Flow (TTM) (Millions $)	109
• Capital Exp. (TTM) (Millions $)	-

CRMD's Profitability Comparisons
Cormedix Inc achieved increase in profitability, due to increase in demand and cost control. Operating Margin grew in second quarter of 2025 to 49.18 % from 21.46 % in IV. Quarter. Cormedix Inc net profit margin of 49.9 % is currently ranking no. 12 in Major Pharmaceutical Preparations industry, ranking no. 20 in Healthcare sector and number 160 in S&P 500.

	*Ratio*
• Capital Ratio (MRQ)	7.82
• Total Debt to Equity (MRQ)	-
• Tangible Leverage Ratio (MRQ)	0.15
• Asset Turnover Ratio (TTM)	0.66
• Inventory Turnover Ratio (TTM)	0.72

CRMD's Profitability Comparisons

Cormedix Inc achieved increase in profitability, due to increase in demand and cost control. Operating Margin grew in second quarter of 2025 to 49.18 % from 21.46 % in IV. Quarter.

Cormedix Inc net profit margin of 49.9 % is currently ranking no. 12 in Major Pharmaceutical Preparations industry, ranking no. 20 in Healthcare sector and number 160 in S&P 500.

• More on CRMD's Key Ratios

Help

About us

Terms of Use

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.